Lymphoproliferative disorders and chemokines

Vito Pistoia, A. Corcione, F. Dallegri, L. Ottonello

Research output: Contribution to journalArticle

Abstract

Chemokines are low molecular weight cytokines specialized in leukocyte recruitment. Recent studies have shown that tumor cells of hematopoietic and non hematopoietic origin express different chemokine receptors that may be involved in neoplastic cell growth, metastasis and angiogenesis. Human lymphoproliferative disorders arise from the malignant transformation of normal lymphoid cells frozen at discrete maturational stages. Studies performed with acute or chronic lymphoproliferative disorders have shown that CXCR4, the unique receptor for CXCL12, is up-regulated in many B and T cells malignancies and may be involved in metastatic localization of the neoplastic elements. Additional chemokine receptors are expressed in the individual lymphoproliferative disorders, but some of these are often non functional. Here we shall review the state of the art on chemokine receptor expression and function in human lymphoproliferative disorders, stressing the potential value of chemokines receptors as novel therapeutic targets. In this respect, small antagonistic peptides are being produced by pharmaceutical companies and hold great promise for clinical application.

Original languageEnglish
Pages (from-to)81-90
Number of pages10
JournalCurrent Drug Targets
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Lymphoproliferative Disorders
Chemokine Receptors
Chemokines
CXCR4 Receptors
T-cells
Cell growth
Tumors
Neoplasms
Leukocytes
B-Lymphocytes
Molecular Weight
Molecular weight
Cells
Lymphocytes
Cytokines
Neoplasm Metastasis
T-Lymphocytes
Peptides
Growth
Pharmaceutical Preparations

Keywords

  • Chemokine receptors
  • Immunophenotype
  • Lymphoproliferative disorder
  • Multiple Myeloma
  • Osteoclast activation
  • Tumor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Lymphoproliferative disorders and chemokines. / Pistoia, Vito; Corcione, A.; Dallegri, F.; Ottonello, L.

In: Current Drug Targets, Vol. 7, No. 1, 01.2006, p. 81-90.

Research output: Contribution to journalArticle

Pistoia, Vito ; Corcione, A. ; Dallegri, F. ; Ottonello, L. / Lymphoproliferative disorders and chemokines. In: Current Drug Targets. 2006 ; Vol. 7, No. 1. pp. 81-90.
@article{06aa1020e5364e6bbdf3b02a5a8afd46,
title = "Lymphoproliferative disorders and chemokines",
abstract = "Chemokines are low molecular weight cytokines specialized in leukocyte recruitment. Recent studies have shown that tumor cells of hematopoietic and non hematopoietic origin express different chemokine receptors that may be involved in neoplastic cell growth, metastasis and angiogenesis. Human lymphoproliferative disorders arise from the malignant transformation of normal lymphoid cells frozen at discrete maturational stages. Studies performed with acute or chronic lymphoproliferative disorders have shown that CXCR4, the unique receptor for CXCL12, is up-regulated in many B and T cells malignancies and may be involved in metastatic localization of the neoplastic elements. Additional chemokine receptors are expressed in the individual lymphoproliferative disorders, but some of these are often non functional. Here we shall review the state of the art on chemokine receptor expression and function in human lymphoproliferative disorders, stressing the potential value of chemokines receptors as novel therapeutic targets. In this respect, small antagonistic peptides are being produced by pharmaceutical companies and hold great promise for clinical application.",
keywords = "Chemokine receptors, Immunophenotype, Lymphoproliferative disorder, Multiple Myeloma, Osteoclast activation, Tumor",
author = "Vito Pistoia and A. Corcione and F. Dallegri and L. Ottonello",
year = "2006",
month = "1",
doi = "10.2174/138945006775270187",
language = "English",
volume = "7",
pages = "81--90",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Lymphoproliferative disorders and chemokines

AU - Pistoia, Vito

AU - Corcione, A.

AU - Dallegri, F.

AU - Ottonello, L.

PY - 2006/1

Y1 - 2006/1

N2 - Chemokines are low molecular weight cytokines specialized in leukocyte recruitment. Recent studies have shown that tumor cells of hematopoietic and non hematopoietic origin express different chemokine receptors that may be involved in neoplastic cell growth, metastasis and angiogenesis. Human lymphoproliferative disorders arise from the malignant transformation of normal lymphoid cells frozen at discrete maturational stages. Studies performed with acute or chronic lymphoproliferative disorders have shown that CXCR4, the unique receptor for CXCL12, is up-regulated in many B and T cells malignancies and may be involved in metastatic localization of the neoplastic elements. Additional chemokine receptors are expressed in the individual lymphoproliferative disorders, but some of these are often non functional. Here we shall review the state of the art on chemokine receptor expression and function in human lymphoproliferative disorders, stressing the potential value of chemokines receptors as novel therapeutic targets. In this respect, small antagonistic peptides are being produced by pharmaceutical companies and hold great promise for clinical application.

AB - Chemokines are low molecular weight cytokines specialized in leukocyte recruitment. Recent studies have shown that tumor cells of hematopoietic and non hematopoietic origin express different chemokine receptors that may be involved in neoplastic cell growth, metastasis and angiogenesis. Human lymphoproliferative disorders arise from the malignant transformation of normal lymphoid cells frozen at discrete maturational stages. Studies performed with acute or chronic lymphoproliferative disorders have shown that CXCR4, the unique receptor for CXCL12, is up-regulated in many B and T cells malignancies and may be involved in metastatic localization of the neoplastic elements. Additional chemokine receptors are expressed in the individual lymphoproliferative disorders, but some of these are often non functional. Here we shall review the state of the art on chemokine receptor expression and function in human lymphoproliferative disorders, stressing the potential value of chemokines receptors as novel therapeutic targets. In this respect, small antagonistic peptides are being produced by pharmaceutical companies and hold great promise for clinical application.

KW - Chemokine receptors

KW - Immunophenotype

KW - Lymphoproliferative disorder

KW - Multiple Myeloma

KW - Osteoclast activation

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=33644920656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644920656&partnerID=8YFLogxK

U2 - 10.2174/138945006775270187

DO - 10.2174/138945006775270187

M3 - Article

C2 - 16454701

AN - SCOPUS:33644920656

VL - 7

SP - 81

EP - 90

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 1

ER -